Article
Urology & Nephrology
Pierre-Louis Reignier, Helene Gauthier, Christophe Hennequin, Quiterie Aussedat, Evanguelos Xylinas, Francois Desgrandchamps, Stephane Culine, Alexandra Masson-Lecomte, Clement Dumont
Summary: This study aimed to assess the outcomes of patients with localized muscle-invasive bladder cancer (MIBC) treated either by radical cystectomy (RC) or trimodal treatment (TMT) based on the pathological response to neoadjuvant chemotherapy (NAC). It was found that TMT, for patients with favorable pathological response to NAC, had similar favorable oncological outcomes as RC.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Oncology
Se Young Choi, Moon Soo Ha, Byung Hoon Chi, Jin Wook Kim, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, Myoungsuk Kim, Kyung-Eun Lee, Yuwon Kim, Hyun-Ki Woo, Dae-Sung Kyoung, Hasung Kim
Summary: This study compared the perioperative outcomes, overall survival, and treatment trends in patients with bladder cancer who underwent radical cystectomy and received either neoadjuvant or adjuvant chemotherapy. The findings suggest that neoadjuvant chemotherapy is associated with better overall survival and lower administration of granulocyte colony-stimulating factor when compared to adjuvant chemotherapy. Therefore, neoadjuvant chemotherapy should be considered as a treatment option for bladder cancer patients undergoing radical cystectomy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Polat Turker, Mona-Lisa Wernroth, Per-Uno Malmstrom, Ulrika Segersten, Tammer Hemdan
Summary: A study demonstrated that CCTa biomarker could serve as a predictive tool for guiding the efficacy of neoadjuvant chemotherapy in bladder cancer patients, while the predictive value of other biomarkers was limited. Combining CCTa with other biomarkers might enhance the predictive ability of NAC efficacy in patients, potentially reducing the number needed to treat.
TRANSLATIONAL RESEARCH
(2021)
Article
Urology & Nephrology
Francesco Soria, Peter C. Black, Adrian S. Fairey, Michael S. Cookson, Evan Y. Yu, Wassim Kassouf, Marc A. Dall'Era, Srikala S. Sridhar, John S. McGrath, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Siamak Daneshmand, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Jay B. Shah, Bas W. van Rhijn, Philippe E. Spiess, Shahrokh F. Shariat, Paolo Gontero
Summary: In patients with cT2N0 bladder cancer and no preoperative hydronephrosis, neoadjuvant chemotherapy (NAC) increased the rate of pathological complete response and downstaging, showing a positive impact on overall survival.
Review
Health Care Sciences & Services
Hadi Shsm, Usama A. Fahmy, Nabil A. Alhakamy, Mohd G. Khairul-Asri, Omar Fahmy
Summary: The use of immune checkpoint inhibitors in neoadjuvant treatment for bladder cancer before radical cystectomy shows promising results, but further studies with extended follow-up are needed to determine the true impact on survival benefits.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Shane Kronstedt, Sai Krishnaraya Doppalapudi, Joseph Boyle, Kevin Chua, Thomas L. Jang, Giovanni E. Cacciamani, Saum Ghodoussipour
Summary: This study aimed to assess the survival benefit for different times to adjuvant chemotherapy after radical cystectomy. Four selected studies showed that an earlier administration of adjuvant chemotherapy could provide a survival benefit.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Giuseppe Basile, Marco Bandini, Ewan A. Gibb, Jeffrey S. Ross, Daniele Raggi, Laura Marandino, Tiago Costa de Padua, Emanuele Crupi, Renzo Colombo, Maurizio Colecchia, Roberta Lucian, Luigi Nocera, Marco Moschini, Alberto Briganti, Francesco Montorsi, Andrea Necchi
Summary: The PURE-01 study confirms the sustained efficacy of neoadjuvant immune-checkpoint inhibitor therapy in patients with muscle-invasive urothelial bladder carcinoma (MIBC). PD-L1 expression is the strongest predictor of sustained response post-RC.
CLINICAL CANCER RESEARCH
(2022)
Article
Andrology
Zhiyong Cai, Hang Jin, Jinbo Chen, Jiao Hu, Huihuang Li, Zhenglin Yi, Xiongbing Zu
Summary: The study indicates that adjuvant chemotherapy after neoadjuvant chemotherapy and radical cystectomy can improve overall survival and cancer-specific survival for patients with locally advanced bladder cancer.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2021)
Article
Oncology
Andrew T. Gabrielson, Marcus J. Daniels, Julian Rowe, Ridwan Alam, Esther J. Lee, Andres Matoso, Anthony De Felice, Noah Hahn, Jean Hoffman-Censits, Trinity J. Bivalacqua, Max Kates
Summary: The study aims to better define surrogate endpoints for neoadjuvant chemotherapy (NAC) trials in patients with muscle-invasive bladder cancer. The results show that patients with residual carcinoma in-situ (CIS) after NAC and radical cystectomy (RC) have similar survival outcomes compared to those with a complete response (CR).
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Vedang Murthy, Ganesh Bakshi, Jifmi Jose Manjali, Gagan Prakash, Mahendra Pal, Amit Joshi, Kunal Dholakia, Atanu Bhattacharjee, Sanjay Talole, Abhinav Puppalwar, Shashank Srinivasan, Gitanjali Panigrahi, Rohan Salunkhe, Santosh Menon, Vanita Noronha, Kumar Prabhash, Rahul Krishnatry
Summary: The study reported patterns of locoregional recurrence (LRR) in muscle invasive bladder cancer (MIBC) and proposed a risk stratification to predict LRR for optimizing the indication for adjuvant radiotherapy. The cohort was divided into low risk (LR), intermediate risk (IR), and high risk (HR) groups based on T, N, and LVI scores, with the HR group having a cumulative incidence of 35% LRR. The findings suggest that the proposed risk stratification model can guide in tailoring adjuvant radiotherapy in MIBC.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Giuseppe Lucarelli, Daniela Terracciano, Daniela Pacella, Tommaso Muto, Angelo Porreca, Gian Maria Busetto, Francesco Del Giudice, Francesco Soria, Paolo Gontero, Francesco Cantiello, Rocco Damiano, Fabio Crocerossa, Abdal Rahman Abu Farhan, Riccardo Autorino, Mihai Dorin Vartolomei, Matteo Muto, Michele Marchioni, Andrea Mari, Luca Scafuri, Andrea Minervini, Nicola Longo, Francesco Chiancone, Sisto Perdona, Pietro De Placido, Antonio Verde, Michele Catellani, Stefano Luzzago, Francesco Alessandro Mistretta, Pasquale Ditonno, Vincenzo Francesco Caputo, Michele Battaglia, Stefania Zamboni, Alessandro Antonelli, Francesco Greco, Giorgio Ivan Russo, Rodolfo Hurle, Nicolae Crisan, Matteo Manfredi, Francesco Porpiglia, Giuseppe Di Lorenzo, Felice Crocetto, Carlo Buonerba
Summary: In a multicenter retrospective study involving patients with urothelial bladder cancer, receiving three cycles of neoadjuvant cisplatin-gemcitabine was found to be equally effective, with potentially lower long-term toxicity, compared to four cycles.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
Joshua S. Jue, Tulay Koru-Sengul, Feng Miao, Maria C. Velasquez, Luis F. Savio, Mahmoud Alameddine, Zachary A. Kroeger, Sanoj Punnen, Dipen J. Parekh, Chad R. Ritch, Mark L. Gonzalgo
Summary: The study found that patients who received neoadjuvant chemotherapy had better 5-year survival rates and less disease progression. Therefore, neoadjuvant chemotherapy combined with radical cystectomy can improve survival rates for patients with T2-T4, N0, M0 bladder cancer.
MINERVA UROLOGY AND NEPHROLOGY
(2021)
Article
Oncology
Siv Venkat, Aleem Khan, Benjamin L. Taylor, Neal A. Patel, Bashir Al Hussein Al Awamlh, Lina Posada Calderon, Jonathan Fainberg, Jonathan Shoag, Douglas S. Scherr
Summary: The use of neoadjuvant chemotherapy (NAC) reduces the sex-specific survival disparities in patients with advanced bladder cancer, although female patients still have poorer survival outcomes in the absence of NAC. Strategies should be implemented to improve the utilization of NAC in women to overcome potential sex-specific differences in diagnosis, disease stage, or tumor biology that contribute to differences in survival outcomes.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Oncology
Ziwei Zhu, Yunyuan Xiao, Shengye Hu, Ziyuan Wang, Zaisheng Zhu
Summary: For patients with variant histology bladder cancers, neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) can improve overall survival (OS) and cancer-specific survival (CSS) compared with radical cystectomy alone. NAC benefits the sarcomatoid and neuroendocrine subgroups, while only the neuroendocrine subgroup shows improved CSS with AC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Urology & Nephrology
Janneke E. W. Walraven, Theodora M. Ripping, Jorg R. Oddens, Bas W. G. van Rhijn, Catharina A. Goossens-Laan, Maarten C. C. M. Hulshof, Lambertus A. Kiemeney, J. A. Witjes, Valery E. P. P. Lemmens, Jacobus J. M. van der Hoeven, Ingrid M. E. Desar, Katja K. H. Aben, Rob H. A. Verhoeven
Summary: This study investigated the role of specialised genitourinary multidisciplinary team meetings (MDTMs) in decision-making and identified factors that influenced the probability of receiving treatment with curative intent for patients with muscle invasive bladder cancer (MIBC). The study found that age, performance status, and the type of hospital were associated with the likelihood of being discussed in an MDTM and receiving curative treatment. Patient preference was the main reason for non-adherence to treatment advice.
Article
Oncology
Jolanda C. van Hoeve, Rob H. A. Verhoeven, Wouter B. Nagengast, Vera Oppedijk, Mitchell G. Lynch, Johan M. van Rooijen, Patrick Veldhuis, Sabine Siesling, Ewout A. Kouwenhoven
Summary: This study aimed to investigate the variation in esophageal cancer care between hospitals in the Managed Clinical Network (MCN) in the Netherlands. The results showed that there were differences in treatment strategies, lead time to treatment initiation, and 2-year survival rates among the hospitals in the MCN network from 2012 to 2016.
Article
Oncology
Steven C. Kuijper, Marieke Pape, Nadia Haj Mohammad, Theo van Voorthuizen, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: The study developed a new clinical prediction model called SOURCE beyond first-line, which predicted survival for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy. The model was developed using patient, tumor, and treatment characteristics, and was internally validated, demonstrating good predictive performance and calibration.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Josianne C. H. B. M. Luijten, Pauline A. J. Vissers, Julie Geerts, Valery E. P. Lemmens, Richard van Hillegersberg, Laurens Beerepoot, Janneke E. W. Walraven, Wouter Curvers, Francine E. M. Voncken, Maurice van der Sangen, Rob H. A. Verhoeven, Grard A. P. Nieuwenhuijzen
Summary: This study investigates national practice variation in the proportion of oesophageal or gastric cancer patients being discussed during an expert Multidisciplinary team meeting (MDTM). The results show significant variation among hospitals and regions regarding the proportion of patients discussed during an expert MDTM, indicating a correlation between the likelihood of being discussed and the diagnosing hospital for patients with oesophageal or gastric cancer.
Article
Oncology
Kammy Keywani, Alexander B. J. Borgstein, Wietse J. Eshuis, Marieke Pape, Kathelijn S. Versteeg, Sarah Derks, Hanneke W. M. van Laarhoven, Suzanne S. Gisbertz, Rob H. A. Verhoeven, Mark van Berge I. Henegouwen
Summary: The generalizability of perioperative chemotherapy trials for gastric cancer to older patients is uncertain. This retrospective cohort study compared the survival outcomes of patients >= 75 years with gastric adenocarcinoma treated with or without neoadjuvant chemotherapy. The overall survival was not significantly different between patients >= 75 years treated with or without neoadjuvant chemotherapy, but a higher proportion of patients >= 75 years did not proceed to surgery following neoadjuvant chemotherapy compared to younger patients.
Article
Oncology
Steven C. Kuijper, Marieke Pape, Pauline A. J. Vissers, Paul M. Jeene, Ewout A. Kouwenhoven, Nadia Haj Mohammad, Jelle P. Ruurda, Meindert N. Sosef, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: New treatment options and centralization of surgery have improved survival for patients with non-metastatic esophageal or gastric cancer. The aim of this study was to identify best-case, typical and worst-case scenarios in terms of survival time, and to assess if survival associated with these scenarios changed over time. Survival improved for almost all patients suggesting that in clinical practice the vast majority of patients benefitted from treatment advances. The clinically most meaningful survival advantage was observed for the best-case scenario of esophageal cancer.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Surgery
Irma C. C. Noordzij, Marije L. L. Hazen, Grard A. P. Nieuwenhuijzen, Rob H. A. Verhoeven, Erik J. J. Schoon
Summary: The proportion of patients receiving endoscopic treatment for early oesophageal and gastro-oesophageal junction cancer in the Netherlands increased over time, while the proportion receiving surgery decreased. The 5-year relative survival after endoscopic treatment was high and comparable to surgery.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Oncology
Janneke E. W. Walraven, Rob H. A. Verhoeven, Jacobus J. M. van der Hoeven, Renske van der Meulen, Valery E. P. P. Lemmens, Gijs Hesselink, Ingrid M. E. Desar
Summary: Nowadays, multidisciplinary team meetings (MDTM) for cancer patients are becoming unsustainable due to the increasing number of patients. To address this issue, streamlining and computerised clinical decision support systems (CCDSSs) are proposed as two major ways to restructure MDTMs. Streamlining involves selecting patients for discussion and determining the type of MDTM, while CCDSSs automatically load patient data and generate guideline-based treatment proposals. However, physicians still have concerns about the value of CCDSSs.
FRONTIERS IN ONCOLOGY
(2023)
Article
Health Care Sciences & Services
Janneke E. W. Walraven, Rob H. A. Verhoeven, Renske van der Meulen, Jacobus J. M. van der Hoeven, Valery E. P. P. Lemmens, Gijs Hesselink, Ingrid M. E. Desar
Summary: This study aims to identify the facilitators and barriers to conducting an efficient, competent, and high-quality multidisciplinary team meeting (MDTM) in oncological care. The findings reveal that organizational aspects, participants' responsibilities and requirements, competences, behavior and team dynamics, and meeting content are crucial factors for an optimal MDTM. Good organization, a sound structure, and functioning information and communication technology contribute to high-quality MDTMs, while multidisciplinary collaboration and adequate communication are essential competences for participants. Hierarchy and inadequate communication act as hindering factors.
Article
Oncology
Felice N. van Erning, Grard A. P. Nieuwenhuijzen, Hanneke W. M. van Laarhoven, Camiel Rosman, Suzanne S. Gisbertz, Joos Heisterkamp, Sjoerd M. Lagarde, Marije Slingerland, Jan-Willem van den Berg, Ewout A. Kouwenhoven, Rob H. A. Verhoeven, Pauline A. J. Vissers
Summary: This study examines the incidence of gastrointestinal symptoms after resection of esophageal or gastric cancer and their impact on health-related quality of life, functioning, work productivity, and daily activities. Results show that gastrointestinal symptoms significantly change over time after the surgery and have a negative impact on patients' overall well-being and daily functioning.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Felice N. van Erning, Nynke E. M. Greidanus, Rob H. A. Verhoeven, Jeroen Buijsen, Hans W. de Wilt, Dorothea Wagner, Geert-Jan Creemers
Summary: This study analyzed gender differences in incidence, tumor characteristics, treatment, and relative survival in colorectal cancer. It found significant gender differences in incidence, tumor characteristics, treatment, and relative survival in patients with colorectal cancer. Particularly, women over 71 years of age were less likely to receive systemic therapy and more likely to receive best supportive care only.
CANCER EPIDEMIOLOGY
(2023)
Article
Oncology
Marianne C. Kalff, Willemieke P. M. Dijksterhuis, Anna D. Wagner, Sabine Oertelt-Prigione, Rob H. A. Verhoeven, Valery E. P. P. Lemmens, Hanneke W. M. van Laarhoven, Suzanne S. Gisbertz, Mark I. van Berge Henegouwen
Summary: Although the curative treatment options are the same for male and female gastroesophageal cancer patients, there may be differences in access to care and survival. This study aimed to compare treatment allocation and survival between male and female patients with potentially curable gastroesophageal cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Marieke Pape, Pauline A. J. Vissers, Marije Slingerland, Nadia Haj Mohammad, Peter S. N. van Rossum, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven, DUCG
Summary: This study investigated the impact of systemic therapy on the health-related quality of life in patients with advanced esophagogastric cancer. The results showed significant improvements in symptoms such as odynophagia, anxiety, and dysphagia during systemic therapy. However, there was a significant deterioration in quality of life at and after disease progression.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Medicine, General & Internal
Merel J. M. van Velzen, Michelle Braemer, Grard A. P. Nieuwenhuijzen, Johanna W. van Sandick, Peter D. Siersema, Jelle P. Ruurda, Marcel Verheij, Manon C. W. Spaander, Laurens V. Beerepoot, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven
Summary: This study aimed to analyze the trends in incidence, staging, and treatment of gastric cancer. The results showed a decrease in incidence, more accurate staging, a shift in treatment modalities, and improved patient survival.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)